Nirsevimab's Impact on Infant RSV Outcomes in Quebec

Nirsevimab effectiveness, number needed to immunize and impact on severe

RSV outcomes in preterm, high-risk and healthy-term infants, Quebec,

Canada

Sara Carazo, MD PhD1,2,3 – Manale Ouakki, MSc3 – Danuta M Skowronski, MD FRCPC4 –

Maude Paquette, MD5,6,7 – Nicholas Brousseau, MD MSc FRCPC1,2,3 – Denis Talbot,

PhD1,2 – Charles-Antoine Guay, MD MSc1,3 – Caroline Quach, MD MSc5,6 – Rodica Gilca,

MD PhD1,2,3 – Jesse Papenburg, MD MSc8,9

1Social and preventive medicine department, Faculty of medicine, Laval University, Québec,

Québec, Canada

2Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Québec,

Québec, Canada

3Biological risk unit. Institut national de santé publique du Québec, Québec, Québec, Canada

4Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver,

British Columbia, Canada

5Department of Microbiology, University of Montreal, Montréal, Canada

6Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montréal, Québec, Canada

7Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-

Anne-de-Bellevue, Québec, Canada

8Departement of pediatric, Montreal Children's Hospital of the McGill university Health Centre,

Montréal, Québec, Canada

9Departement of epidemiology, biostatistics and occupational health, Université McGill, Montréal,

Québec, Canada

Corresponding author:

Sara Carazo

Department of social and preventive medicine, Laval University

Institut national de santé publique du Québec

945 Wolfe Avenue, Quebec City, QC, Canada, G1V 5B3

[phone]

[e-mail]; [e-mail]

2